Information Provided By: 
Fly News Breaks for May 26, 2016
IPXL
May 26, 2016 | 06:58 EDT
After analyzing prescription trends and competitive dynamics across Impax Laboratories' generics and brand portfolio, Piper Jaffray analyst David Amsellem believes the company's portfolio is well positioned to deliver "significant" quarterly sequential growth as 2016 progresses. The Adderall XR launch and the uptake of the anti-parasitic Emverm are "notable tailwinds," Amsellem tells investors in a research note. He views Impax's current valuation as attractive and reiterates an Overweight rating on the shares with a $41 price target.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
